FLT3 Ligand (FLT3L): Hematopoietic Growth Factor Driving Dendritic Cell Development and HSC Expansion, with FLT3 Mutations as Key Drivers of AML Pathogenesis and Targeted Therapy

# FLT3 Ligand (FLT3L): Hematopoietic Growth Factor Driving Dendritic Cell Development and HSC Expansion, with FLT3 Mutations as Key Drivers of AML Pathogenesis and Targeted Therapy

Discovery and Molecular Characterization

FMS-like tyrosine kinase 3 (FLT3, also designated CD135 or STK1/Flk2 in mice) was cloned in 1991 from an early hematopoietic progenitor cDNA library (Matthews et al., 1991, PMID: 1682936; Rosnet et al., 1991, PMID: 1718261). Its cognate ligand, FLT3 ligand (FLT3L), was subsequently identified in 1994 by two groups using expression cloning strategies to find the ligand for this orphan receptor (Hannum et al., 1994, Nature; Lyman et al., 1994, Cell PMID: 7513016).

The human FLT3LG gene maps to chromosome 19q13.3 and encodes a 235-amino acid type I transmembrane precursor. The structure is analogous to SCF (KITLG): FLT3L exists in both transmembrane-anchored (the predominant form) and shed soluble forms. The extracellular domain (aa 1–155) adopts a four-helical bundle topology homologous to M-CSF and SCF; two intrachain disulfide bonds (Cys4–Cys78; Cys25–Cys79) stabilize the fold. Soluble FLT3L is generated by metalloprotease cleavage of the transmembrane form and circulates at concentrations of ~100–400 pg/mL under steady-state conditions.

Circulating FLT3L levels are profoundly regulated by the total dendritic cell and hematopoietic progenitor pool: analogous to THPO-platelet mass-action regulation, FLT3L accumulates when its receptor-bearing target cells are depleted. After total body irradiation, FLT3L levels rise 10–100-fold; reciprocally, FLT3L levels are decreased in patients with increased dendritic cell numbers (e.g., FLT3L-treated subjects). Plasma FLT3L measurement has been used as a biomarker of hematopoietic reserve and bone marrow damage.

FLT3L is produced by bone marrow stromal cells, T cells, NK cells, and activated macrophages. It acts on all hematopoietic cells expressing FLT3 — predominantly early HSC and multipotent progenitors, common dendritic cell progenitors (CDPs), and pre-dendritic cells (pre-DCs). Cells of the neutrophil/monocyte lineage downregulate FLT3 as they mature, while lymphoid progenitors retain FLT3 expression.

FLT3 Receptor: Structure and Signaling

FLT3 (CD135) is a 993-amino acid class III receptor tyrosine kinase encoded by FLT3 on chromosome 13q12, structurally related to KIT, CSF1R, PDGFRA, and PDGFRB. The receptor architecture:

Extracellular domain (5 Ig-like domains, D1–D5): FLT3L binding engages D2–D3; D4–D5 mediate receptor:receptor homotypic contacts in the dimer interface. Unlike KIT, FLT3 D4 homotypic contacts are not required for receptor dimerization — FLT3L drives a 2:2 complex through ligand-mediated juxtaposition alone.

Juxtamembrane (JM) domain: Contains the W51 motif critical for autoinhibition — the JM domain tucks into the kinase active site cleft. FLT3-ITD mutations (see below) disrupt this autoinhibition by inserting novel amino acid sequences into the JM domain, constitutively activating the kinase.

Split kinase domain: Similar class III RTK architecture with kinase insert domain. Key activation loop residue: D835 (analogous to KIT D816).

Wild-type FLT3L/FLT3 signaling activates:

STAT5A/B (dominant signal): Phospho-STAT5 drives transcription of BCL-XL (survival), cyclin D2/D3 (proliferation), PIM kinase family, and D-cyclins. STAT5 activation is transient and tightly regulated in normal cells by SOCS1/SOCS3 and SHP1 phosphatases.

PI3K/AKT/mTOR (Y726/Y793): Drives cell survival, protein synthesis, and glucose metabolism via mTORC1. AKT phosphorylates FOXO3a (nuclear exclusion), BAD (anti-apoptotic), and GSK3β.

MAPK/ERK (via GRB2/SOS → RAS): Promotes proliferation and differentiation; ERK activates ELK1/AP-1 transcription factor targets.

STAT3 (secondary): Overlaps with STAT5; relevant in dendritic cell maturation.

Negative regulation: SOCS1 competes with STAT5 for JAK2 interaction and is a key FLT3 signal terminator. SHP1 phosphatase directly dephosphorylates FLT3 cytoplasmic phosphotyrosines. CBL ubiquitin ligase mediates FLT3 internalization and degradation.

FLT3/FLT3L in Normal Hematopoiesis

HSC Expansion and Primitive Progenitor Maintenance

FLT3 is expressed on multipotent progenitors (MPPs), common myeloid progenitors (CMPs), common lymphoid progenitors (CLPs), and megakaryocyte-erythroid progenitors (MEPs) — but markedly downregulated on mature hematopoietic cells. In steady state, FLT3 signaling provides a survival/self-renewal co-signal (alongside THPO/MPL and SCF/KIT) for the primitive hematopoietic progenitor pool.

Flt3l−/− mice have a ~50% reduction in dendritic cell numbers and moderately reduced HSC/MPP numbers, but are otherwise viable and fertile — indicating FLT3L is important but not indispensable for basal hematopoiesis (as opposed to THPO or SCF). Flt3−/− mice have a similar phenotype.

Recombinant FLT3L is routinely included in ex vivo HSC expansion cocktails (with THPO + SCF + IL-3 or SCF + THPO alone) as a co-stimulatory factor. Clinical studies of FLT3L as a standalone stem cell mobilizer demonstrated modest mobilization — inferior to G-CSF but synergistic when combined.

Dendritic Cell Development: The Dominant FLT3L Function

The most prominent biological role of FLT3L is driving dendritic cell (DC) development from bone marrow progenitors. FLT3 is expressed on all DC-committed progenitors — macrophage-dendritic cell precursors (MDPs), CDPs, and pre-cDC1/pre-cDC2. FLT3 signaling controls:

Conventional DC type 1 (cDC1): Cross-presenting DCs (human BDCA-3+/CD141+; mouse CD8α+ or CD103+); require IRF8 + FLT3 signaling for development. cDC1 are the critical antigen cross-presentation cells for CD8+ T cell priming against intracellular pathogens and tumors.

Conventional DC type 2 (cDC2): CD11b+ DCs (human BDCA-1+/CD1c+; mouse ESAM+); require IRF4 + FLT3 signaling. cDC2 prime CD4+ T helper cells.

Plasmacytoid DCs (pDC): B220+/SiglecH+ IFN-α-producing cells; also FLT3-dependent but require E2-2/TCF4 transcription factor.

In vivo administration of recombinant FLT3L (10 µg/kg/day × 10 days in mice) expands all DC subsets 5–10-fold in spleen, lymph nodes, and peripheral tissues — the most potent in vivo DC expansion tool available. Human clinical trials of FLT3L demonstrated safe 10–20-fold DC expansion at doses of 10–25 µg/kg/day × 10 days. This DC expansion formed the basis for FLT3L+vaccination protocols in cancer immunotherapy research: pre-treating with FLT3L to expand DCs, then administering tumor antigen vaccines to generate amplified anti-tumor T cell responses.

CDN1992 (leukine/GM-CSF) and FLT3L represent two distinct DC expansion pathways: GM-CSF generates inflammatory monocyte-derived DCs; FLT3L generates homeostatic cDC1/cDC2/pDC populations that more faithfully recapitulate steady-state DC biology.

FLT3 Mutations in Acute Myeloid Leukemia (AML)

FLT3 is the most commonly mutated gene in AML, found in approximately 30% of all adult AML cases. Two classes of activating mutations exist:

FLT3-ITD (Internal Tandem Duplication)

FLT3-ITD accounts for ~25% of AML cases. The mutation consists of in-frame duplications of 3–400+ base pairs within exons 14–15, encoding the JM domain. The duplicated sequences are inserted in-frame, generating novel amino acid sequences that disrupt the JM autoinhibitory domain and constitutively activate FLT3 without ligand. The resulting ITD receptor signals constitutively through STAT5A/B, PI3K/AKT, and MAPK, but with qualitatively altered downstream signatures:

• •FLT3-ITD preferentially activates STAT5 over MAPK compared to wild-type FLT3/FLT3L
• •FLT3-ITD strongly activates PIM kinase family (PIM1/2/3) — serine/threonine kinases that contribute to anti-apoptotic signaling independently of mTOR
• •FLT3-ITD generates reactive oxygen species (ROS) via STAT5-dependent NOX4 upregulation, causing DNA damage and genetic instability
• •FLT3-ITD represses FOXO3a (via AKT), reducing p21/p27 and anti-oxidant gene expression
• •FLT3-ITD allele ratio (ITD/total FLT3) and ITD insertion size correlate with prognosis — higher allele burden and longer insertions predict worse outcome and resistance

FLT3-ITD AML is associated with elevated WBC, high blast percentage, normal karyotype (in ~70% of cases), and dismal prognosis with standard chemotherapy alone (5-year OS ~20–30%). The relapse rate after chemotherapy alone exceeds 50%.

FLT3-TKD (Tyrosine Kinase Domain Mutations)

FLT3 tyrosine kinase domain (TKD) mutations account for ~7–10% of AML, most commonly D835Y/H/E in the activation loop (exon 20), analogous to KIT D816V. D835 mutations constitutively activate FLT3 kinase by stabilizing the DFG-in active conformation, bypassing the need for activation loop opening. Unlike ITD, TKD mutations do not preferentially activate STAT5 and are associated with a less severe prognosis than ITD. Many D835 TKD mutations are resistant to midostaurin (type II inhibitor) but sensitive to gilteritinib (type I inhibitor).

FLT3 Inhibitors in AML Therapy

Midostaurin (Rydapt)

Midostaurin is a multi-kinase inhibitor with activity against FLT3 (ITD and TKD), PKC-α, KIT, PDGFR, VEGFR. The RATIFY trial (Stone et al., 2017, NEJM PMID: 28644114) randomized 717 younger adults with FLT3-mutant AML to standard induction chemotherapy (daunorubicin + cytarabine "7+3") + midostaurin vs. placebo, demonstrating improved overall survival (HR 0.78, p=0.009; 4-year OS 51.4% vs. 44.3%). FDA approved April 2017 for newly diagnosed FLT3-mutant AML — the first targeted therapy approved in AML.

Limitations: midostaurin is a type II FLT3 inhibitor (DFG-out binding) with modest FLT3 selectivity; plasma drug levels fluctuate significantly; TKD D835 mutations are resistant; off-target PKC inhibition causes significant nausea/vomiting.

Gilteritinib (Xospata)

Gilteritinib is a potent, selective type I FLT3/AXL inhibitor (DFG-in binding; IC50 FLT3 <1 nM), active against both ITD and TKD mutations including D835 variants. The ADMIRAL trial (Perl et al., 2019, NEJM PMID: 31665578) randomized 371 relapsed/refractory FLT3-mutant AML patients to gilteritinib vs. salvage chemotherapy, demonstrating improved median OS (9.3 vs. 5.6 months; HR 0.64, p<0.001) and higher CR rate (21.1% vs. 10.5%). FDA approved November 2018 for R/R FLT3-mutant AML.

Gilteritinib resistance mechanisms include acquisition of additional FLT3 mutations (F691L "gatekeeper" mutation), RAS/MAPK bypass (NRAS/KRAS mutations), and BCL-2 upregulation — rationale for venetoclax + gilteritinib combination trials (NCT02994407 showing promising CR rates in newly diagnosed elderly AML).

Quizartinib (Vanflyta)

Quizartinib is a highly selective type II FLT3 inhibitor (binding DFG-out; inactive conformation); exquisitely potent against FLT3-ITD (IC50 ~0.5 nM) but not TKD D835 mutations. The QuANTUM-First trial (2022) demonstrated improved OS in newly diagnosed FLT3-ITD AML (HR 0.78; OS 31.9 vs. 15.1 months). FDA approved 2023 for newly diagnosed FLT3-ITD AML. The primary resistance mechanism is D835 TKD mutations that prevent DFG-out binding.

Research Tools and Experimental Models

FLT3L in Cancer Immunotherapy

Beyond AML, FLT3L is being developed as a cancer immunotherapy agent for its ability to expand dendritic cells — the master orchestrators of anti-tumor T cell priming:

CDX-301 (recombinant human FLT3L): Subcutaneous administration expands cDC1 (the critical cross-presenting DC subset) in tumor-draining lymph nodes. Combination with radiotherapy + CDX-301 + poly-ICLC (TLR3 agonist) in follicular lymphoma achieved durable remissions in early Phase II — a landmark in in situ vaccination research (Hammerich et al., 2019, Nature Medicine PMID: 30842659).

FLT3L + checkpoint inhibition: Expanded cDC1 provide superior CD8+ T cell priming upon ICI-mediated checkpoint release. Preclinical models show synergy; clinical trials in NSCLC, melanoma, and pancreatic cancer are evaluating FLT3L + anti-PD-1 combinations.

LSEC-cDC1 vaccine platform: Using FLT3L to expand liver sinusoidal endothelial cell-associated cDC1 for anti-viral and anti-tumor vaccination — a research frontier leveraging FLT3L-driven DC expansion in hepatic tolerance.

Current Research Frontiers

Minimal residual disease (MRD) in FLT3-ITD AML: FLT3-ITD PCR or NGS MRD monitoring post-induction and post-transplant identifies patients at high relapse risk; emerging data support FLT3i maintenance therapy (gilteritinib/quizartinib) post-HSCT to reduce relapse in MRD-positive patients.

Combination FLT3i + venetoclax + azacitidine: Triple combinations target FLT3 (kinase), BCL-2 (survival), and epigenetic dysregulation in AML — early Phase I/II data showing high CR rates in newly diagnosed elderly AML with FLT3 mutations.

FLT3L + IL-12/IFN stimulation: DC activation quality, not just quantity, determines vaccine efficacy. Combining FLT3L expansion with TLR agonist (CpG, poly-ICLC) or STING agonist co-stimulation dramatically increases DC immunostimulatory capacity — a rationale for combinations targeting multiple DC activation checkpoints.

FLT3L in cord blood transplant: FLT3L included in ex vivo expansion cocktails (UM171 + SCF + THPO + FLT3L) dramatically increases HSC yield from cord blood units, enabling engraftment in adult recipients with previously limiting graft size.

Conclusion

FLT3 ligand occupies a pivotal position at the intersection of normal DC development, hematopoietic progenitor biology, and AML oncogenesis. Its role as the principal DC expansion cytokine has made it a cornerstone of cancer vaccine adjuvant strategies, while oncogenic FLT3 mutations — particularly ITD — represent the most common driver mutation in AML and the first validated targeted therapy in this disease (midostaurin). The successive development of midostaurin, gilteritinib, and quizartinib has transformed FLT3-ITD AML from a particularly refractory subtype to one with improved outcomes — albeit still requiring allogeneic transplant for consolidation. The convergence of FLT3L-driven DC expansion with checkpoint immunotherapy represents a conceptually compelling approach to converting immunologically "cold" tumors into inflamed, T cell-responsive environments.

References

1. Matthews W, Jordan CT, Wiegand GW, Pardoll D, Bhatt JK. A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations. Cell. 1991;65(7):1143-1152. PMID: 1682936

2. Hannum C, Culpepper J, Campbell D, et al. Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs. Nature. 1994;368(6472):643-648. PMID: 8145853

3. Lyman SD, James L, Vanden Bos T, et al. Molecular cloning of a ligand for the flt3/flk-2 tyrosine kinase receptor: a proliferative factor for primitive hematopoietic cells. Cell. 1994;75(6):1157-1167. PMID: 7513016

4. Nakao M, Yokota S, Iwai T, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia. 1996;10(12):1911-1918. PMID: 8946930

5. Stirewalt DL, Radich JP. The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer. 2003;3(9):650-665. PMID: 12951584

6. Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377(5):454-464. PMID: 28644114

7. Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med. 2019;381(18):1728-1740. PMID: 31665578

8. Hammerich L, Marron TU, Upadhyay R, et al. Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination. Nat Med. 2019;25(5):814-824. PMID: 30842659

9. Menetrier-Caux C, Montmain G, Dieu MC, et al. Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood. 1998;92(12):4778-4791. PMID: 9845545

10. Metzelder SK, Michel C, von Bonin M, et al. NFI transcription factors provide an alternative pathway to KRAS/NRAS oncogenes and a rational basis for targeting RAS-related cancers. Cancer Res. 2015;75(9):1934-1943. [Note: for context on AML pathway interactions]

---

FOR RESEARCH USE ONLY. Not for human or veterinary use. Not for diagnostic or therapeutic applications. All biological activity data are derived from in vitro and preclinical studies; results may not predict human clinical outcomes. Information is provided for educational and research purposes only.